Clinical course and outcome of COVID-19 in patients with rheumatic diseases: Are all biological disease-modifying antirheumatic drugs alike? Response to: Â € Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al
Monti S.;Montecucco C.
2020-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.